Low cholesterol? Don't brag yet ... hypocholesterolemia blunts HAART effectiveness: A longitudinal study

Journal of the International AIDS Society

Volumn 13, Issue 1, 2010, Pages

  Míguez, María Jose ^a,b   Lewis, John E ^c   Bryant, Vaughn E ^c   Rosenberg, Rhonda ^b   Burbano, Ximena ^d   Fishman, Joel ^c   Asthana, Deshratn ^c   Duan, Rui ^b   Madhavan, Nair ^a   Malow, Robert M ^b  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Zilonis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ADOLESCENT; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957157469     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-13-25     Document Type: Article

References (46)

1. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. C Grunfeld M Pang W Doerrler JK Shigenaga P Jensen KR Feingold, J Clin Endocrinol Metab 1992 74 1045 52 10.1210/jc.74.5.1045 1373735
2. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus infection. G Shor-Posner A Basit Y Lu C Cabrejos J Chang M Fletcher E Mantero-Atienza MK Baum, Am J Med 1993 94 515 9 10.1016/0002-9343(93)90087-6 7605397
3. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. J Constans JL Pellegrin EJ Peuchant MF Dumon I Pellegrin C Sergeant M Simonoff G Brossard P Barbeau H Fleury M Clerc B Leng C Conri, Eur J Clin Invest 1994 24 416 20 10.1111/j.1365-2362.1994.tb02185.x 7957495
4. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. MK Hellerstein C Grunfeld K Wu M Christiansen S Kaempfer C Kletke CH Shackleton, J Clin Endocrinol Metab 1993 76 559 65 10.1210/jc.76.3.559 8445011
5. Impact of HIV Infection and HAART on Serum Lipids in Men. SA Riddler E Smit SR Cole R Li JS Chmiel A Dobs F Palella B Visscher R Evans LA Kingsley, JAMA 2003 289 2978 2982 10.1001/jama.289.22.2978 12799406
6. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. Z Mujawar H Rose MP Morrow Zahedi T Pushkarsky L Dubrovsky N Mukhamedova Y Fu A Dart KM Orenstein YV Bobryshev M Bukrinsky D Sviridov, PLoS Biol 2006 4 365 10.1371/journal.pbio.0040365 17076584
7. Human immunodeficiency virus infection and macrophage cholesterol metabolism. M Bukrinsky D Sviridov, J Leukoc Biol 2006 80 1044 1051 10.1189/jlb.0206113 17056763
8. Targeting lipids to prevent HIV infection. H Dzung N Taub DD Taub, Mol Interv 2004 4 318 320 10.1124/mi4.6.3 15616159
9. The association between serum total cholesterol and HIV infection in a high risk cohort of young men. AJ Claxton DR Jacobs Jr C Iribarren SL Welles S Sidney KR Feingold, J Acquir Immune Defic Syndr Hum Retroviiol 1998 17 51 7
10. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. C Iribarren DR Jacobs Jr S Sidney AJ Claxton KR Feigold, Epidemiol Bull Infect 1998 121 335 347 10.1017/S0950268898001435
11. Report of the conference on low blood cholesterol: mortality associations. D Jacobs, Circulation 1992 86 1046 1060 1355411
12. MK hypocholesterolemia an independent marker of disease in the era of highly active antiretroviral therapy [abstract]. A Campa MJ Miguez-Burbano G Shor-Posner, XIII International AIDS Conference Durban, South Africa 2000
13. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. E Stein, Atherioscler 2002 1;4 Suppl 2 1 37 10.1016/S0021-9150(01)00664-5
14. NCEP Expert. http://www.nhlbi.nih.gov/guidelines/cholesterol/dskref.htm
15. US national cholesterol guidelines implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone Coordinating Committee of the National Cholesterol Education Program, Arterioscler Thromb Vasc Biol Coordinating Committee of the National Cholesterol Education Program; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association 2004 24 149 161 10.1161/01.ATV.0000133317.49796.0E 15297292
16. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. G Marchetti A Gori A Casabianca A Magnani M Franzetti F Clerici M Perno CF Monforte A d'Arminio G Massimo M Luca The Study Group for Immunologic-non- Responders, AIDS 2006 20 1727 36 10.1097/01.aids.0000242819.72839.db 16931937
17. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection, DHHS/Henry J, http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL05042006050.pdf
18. Priority interventions: HIV/AIDS prevention, treatment and care in the health sector. World Health Organization HIV/AIDS Department, Version 1.2 HIV/AIDS World Health Organization 2009 http://www.who.int/hiv/pub/priority- interventions-web-c1.pdf
19. Alcohol and race/ethnicity elicit different changes in lipid profiles in HIV infected individuals receiving HAART. MJ Míguez-Burbano JE Lewis, J Assoc Nurses AIDS Care 2009 20 176 83 10.1016/j.jana.2009.02.004 19427595
20. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. MJ Míguez-Burbano X Burbano D Ashkin A Rodriguez R Duncan A Pitchenik N Quintero M Flores G Shor-Posner, Addict Biol 2003 8 43 47
21. HIV-associated dyslipidaemia: pathogenesis and treatment. O Jisun RA Hegele, The Lancet Infectious Diseases 2007 7 787 796 10.1016/S1473-3099(07) 70287-6 18045561
22. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. ML Montes F Pulido C Barros E Condes R Rubio C Cepeda F Dronda A Antela J Sanz E Navas P Miralles J Berenguer S Pérez A Zapata JJ Gonzlez-García JM Pẽa JJ Vzquez JR Arribas, J Antimicrob Chemother 2005 55 800 804 10.1093/jac/dki063 15761071
23. IARC, Solar and Ultraviolet Radiation IARC Monographs on the Evaluation of Carcinogenic Risk to Humans 55, Lyon, France: IARC 1992
24. KJ Rothman S Greenland TL Lash, Modern Epidemiology PA, USA: Lippincott Williams & Wilkins 3 2008
25. Statins blunt HAART-induced CD4 T-Cell gains but have no long-term effect on virologic response to HAART. B Rodriguez H Valdez A Mijch, J Int Assoc Physicians AIDS Care (Chic Ill) 2007 6 198 202 10.1177/1545109707300684 17579125
26. Immune system differences in men with hypo- or hypercholesterolemia. MF Muldoon A Marsland JD Flory BS Rabin TL Whiteside SB Manuck, Clin Immunol Immunopathol 1997 84 145 149 10.1006/clin.1997.4382 9245545
27. Cholesterol and sphingolipids as lipid organizers of the immune cells' plasma membrane: their impact on the functions of MHC molecules, effector T-lymphocytes and T-cell death. I Gombos E Kiss C Detre G Laszlo J Matko, Immunol Lett 2006 15 59 69 10.1016/j.imlet.2005.11.021
28. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: correlation with its ability to block culture-induced down-modulation of Bcl-2. Y Adachi N Oyaizu S Than TW McCloskey S Pahwa, J Immunol 1996 157 4184 4193 8892656
29. Effect of T0901317 on hepatic proinflammatory gene expression in apoE-/- mice fed a high-fat/high-cholesterol diet. X Dai X Ou X Hao D Cao Y Tang Y Hu X Li C Tang, Inflammation 2007 30 3-4 105 17 10.1007/s10753-007-9026-2 17516158
30. A clathrin, caveolae, and dynamin-independent endocytic pathway requiring free membrane cholesterol drives HIV-1 internalization and infection in polarized trophoblastic cells. G Vidricaire MJ Tremblay, Journal of Molecular Biology 2007 368 1267 83 10.1016/j.jmb.2007.03.003 17395200
31. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion. AS Rawat M Viard JM Wang A Puri R Blumenthal, Virology Journal 2006 3 104 10.1186/1743-422X-3-104 17187670
32. HIV gp120-induced interaction between CD4 and CCR5 requires cholesterol-rich microenvironments revealed by live cell fluorescence resonance energy transfer imaging. YL Fang JN Isik Ch Jin, Journal of Biological Chemistry 2006 281 35446 53 10.1074/jbc.M601776200 16963439
33. HIV-1 Entry into T-cells Is Not Dependent on CD4 and CCR5 Localization to Sphingolipid-enriched, Detergent-resistant, Raft Membrane Domains. Y Percherancier B Lagane T Planchenault I Staropoli R Altmeyer JL Virelizier F Arenzana-Seisdedos DC Hoessli F Bachelerie, J Biol Chem 2003 278 3153 3161 10.1074/jbc.M207371200 12431990
34. Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. Z Liao DR Graham JE Hildreth, AIDS Research & Human Retroviruses 2003 19 675 87
35. Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. SM Campbell SM Crowe J Mak, AIDS 2002 16 2253 61 10.1097/00002030-200211220-00004 12441796
36. Lipid rafts and membrane dynamics. L Rajendran K Simons, J Cell Sci 2005 118 1099 1102 10.1242/jcs.01681 15764592
37. Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART. E Negredo I Puigdomenech S Marfil J Puig N Perez-Alvarez L Ruiz C Rey-Joly B Clotet J Blanco, Journal of Antimicrobial Chemotherapy 2008 61 400 4 10.1093/jac/dkm470 18083750
38. Evaluation of the anti-HIV activity of statins. G Moncunill E Negredo L Bosch J Vilarrasa M Witvrouw A Llano B Clotet JA Esté AIDS 2005 19 1697 1700 10.1097/01.aids.0000183517.60384.db 16184043
39. High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy. C Alonso-Villaverde T Segues B Coll-Crespo R Perez-Bernalte A Rabassa M Gomila S Parra MA Gozalez-Esteban MJ Jimenez-Exposito L Masana, AIDS 2003 17 1173 1178 10.1097/00002030-200305230-00009 12819519
40. Failure of atorvastatin to modulate CSF HIV-1 infection: Results of a pilot study. JC Probasco SS Spudich J Critchfield E Lee N Lollo SG Deeks RW Price, Neurology 2008 71 521 524 10.1212/01.wnl.0000325006.84658.e7 18695163
41. Pravastatin does not have a consistent effect in chronically HIV-infected individuals on antiretroviral therapy. PA Sklar H Masur JR Grubb J Voell J Witek A Ono EO Freed F Maldarelli, AIDS 2005 19 1109 1112 10.1097/01.aids. 0000174461.31794.50 15958846
42. Lipid rafts and HIV biology Cholesterol is required for HIV-1 infection. Z Liao JE Hildreth Conference on Retroviruses and Opportunistic Infections, Program Abstr 8th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 8th 2001 Chic Ill 2001 8 202 (abstract no. 531)
43. Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business". KA Schoenly DB Weiner, J Virol 2008 82 3166 3180 10.1128/JVI.01634-07 17989174
44. Inflammation and gut permeability. H Byakwaga C Boesecke S Emery, Journal of HIV Therapy 2009 14 57 60 20218240
45. Alcohol, Intestinal Bacterial Growth, Intestinal Permeability to Endotoxin, and Medical Consequences Summary of a Symposium. V Purohit JC Bode D Brenner MA Choudhry F Hamilton Y Kang A Keshavarzian Rao R B Sartor C Swanson JR Turner, Alcohol 2008 42 5 349 361 10.1016/j.alcohol.2008.03.131 18504085
46. Shortage of circulating naive CD8+ T cells provides new insights on immunodeficiency in aging. F Fagnoni R Vescovini G Passeri G Bologna M Pedrazzoni G Lavagetto A Casti C Franceschi M Passeri P Sansoni, Blood 2000 95 2860 2868 10779432